# A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures.

> **NCT00236691** · PHASE2 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 188 (actual)

## Conditions studied

- Epilepsy
- Epilepsies, Partial
- Seizures

## Interventions

- **DRUG:** topiramate

## Key facts

- **NCT ID:** NCT00236691
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1988-07
- **Primary completion:** —
- **Final completion:** 1990-12
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2011-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00236691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00236691, "A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00236691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*